Rebecca J Brown1, Cristina Adelia Meehan1, Elaine Cochran1, Kristina I Rother1, David E Kleiner2, Mary Walter3, Phillip Gorden1. 1. Diabetes, Endocrinology, and Obesity Branch, National Institute of Diabetes and Digestive and Kidney Disease, National Institutes of Health, Bethesda, Maryland 20892. 2. Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892. 3. Clinical Core Laboratory, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892.
Abstract
Context: Lipodystrophy syndromes are rare disorders of deficient adipose tissue. Metreleptin, a human analog of leptin, improved metabolic abnormalities in mixed cohorts of children and adults with lipodystrophy and low leptin. Objective: Determine effects of metreleptin on diabetes, hyperlipidemia, nonalcoholic fatty liver disease (NAFLD), growth, and puberty in pediatric patients with lipodystrophy and low leptin. Design: Prospective, single-arm, open-label studies with continuous enrollment since 2000. Setting: National Institutes of Health, Bethesda, Maryland. Patients: Fifty-three patients aged 6 months to <18 years with lipodystrophy, leptin level <8 ng/mL (male patients) or <12 ng/mL (female patients), and ≥1 metabolic abnormality (diabetes, insulin resistance, or hypertriglyceridemia). Intervention: Subcutaneous metreleptin injections (0.04 to 0.19 mg/kg/d). Main Outcome Measures: Change in A1c, lipid, and transaminase levels after a mean ± standard deviation (SD) of 12 ± 0.2 months and 61 ± 39 months. Changes in liver histology, growth, and pubertal development throughout treatment. Results: After 12 months, the A1c level (mean ± SD) decreased from 8.3% ± 2.4% to 6.5% ± 1.8%, and median triglyceride level decreased from 374 mg/dL [geometric mean (25th,75th percentile), 190, 1065] to 189 mg/dL (112, 334; P < 0.0001), despite decreased glucose- and lipid-lowering medications. The median [geometric mean (25th,75th percentile)] alanine aminotransferase level decreased from 73 U/L (45, 126) to 41 U/L (25, 59; P = 0.001), and that of aspartate aminotransferase decreased from 51 U/L (29, 90) to 26 U/L (18, 42; P = 0.0002). These improvements were maintained over long-term treatment. In 17 patients who underwent paired biopsies, the NAFLD activity score (mean ± SD) decreased from 4.5 ± 2.0 to 3.4 ± 2.0 after 3.3 ± 3.2 years of metreleptin therapy (P = 0.03). There were no clinically significant changes in growth or puberty. Conclusion: Metreleptin lowered A1c and triglyceride levels, and improved biomarkers of NAFLD in pediatric patients with lipodystrophy. These improvements are likely to reduce the lifetime burden of disease.
Context:Lipodystrophy syndromes are rare disorders of deficient adipose tissue. Metreleptin, a human analog of leptin, improved metabolic abnormalities in mixed cohorts of children and adults with lipodystrophy and low leptin. Objective: Determine effects of metreleptin on diabetes, hyperlipidemia, nonalcoholic fatty liver disease (NAFLD), growth, and puberty in pediatric patients with lipodystrophy and low leptin. Design: Prospective, single-arm, open-label studies with continuous enrollment since 2000. Setting: National Institutes of Health, Bethesda, Maryland. Patients: Fifty-three patients aged 6 months to <18 years with lipodystrophy, leptin level <8 ng/mL (male patients) or <12 ng/mL (female patients), and ≥1 metabolic abnormality (diabetes, insulin resistance, or hypertriglyceridemia). Intervention: Subcutaneous metreleptin injections (0.04 to 0.19 mg/kg/d). Main Outcome Measures: Change in A1c, lipid, and transaminase levels after a mean ± standard deviation (SD) of 12 ± 0.2 months and 61 ± 39 months. Changes in liver histology, growth, and pubertal development throughout treatment. Results: After 12 months, the A1c level (mean ± SD) decreased from 8.3% ± 2.4% to 6.5% ± 1.8%, and median triglyceride level decreased from 374 mg/dL [geometric mean (25th,75th percentile), 190, 1065] to 189 mg/dL (112, 334; P < 0.0001), despite decreased glucose- and lipid-lowering medications. The median [geometric mean (25th,75th percentile)] alanine aminotransferase level decreased from 73 U/L (45, 126) to 41 U/L (25, 59; P = 0.001), and that of aspartate aminotransferase decreased from 51 U/L (29, 90) to 26 U/L (18, 42; P = 0.0002). These improvements were maintained over long-term treatment. In 17 patients who underwent paired biopsies, the NAFLD activity score (mean ± SD) decreased from 4.5 ± 2.0 to 3.4 ± 2.0 after 3.3 ± 3.2 years of metreleptin therapy (P = 0.03). There were no clinically significant changes in growth or puberty. Conclusion: Metreleptin lowered A1c and triglyceride levels, and improved biomarkers of NAFLD in pediatric patients with lipodystrophy. These improvements are likely to reduce the lifetime burden of disease.
Authors: M S Cauble; R Gilroy; M F Sorrell; M E Mailliard; D L Sudan; J C Anderson; J L Wisecarver; S Balakrishnan; J L Larsen Journal: Transplantation Date: 2001-04-15 Impact factor: 4.939
Authors: Jean Y Park; Angeline Y Chong; Elaine K Cochran; David E Kleiner; Michael J Haller; Desmond A Schatz; Phillip Gorden Journal: J Clin Endocrinol Metab Date: 2007-10-16 Impact factor: 5.958
Authors: L Van Maldergem; J Magré; T E Khallouf; T Gedde-Dahl; M Delépine; O Trygstad; E Seemanova; T Stephenson; C S Albott; F Bonnici; V R Panz; J L Medina; P Bogalho; F Huet; S Savasta; A Verloes; J J Robert; H Loret; M De Kerdanet; N Tubiana-Rufi; A Mégarbané; J Maassen; M Polak; D Lacombe; C R Kahn; E L Silveira; F H D'Abronzo; F Grigorescu; M Lathrop; J Capeau; S O'Rahilly Journal: J Med Genet Date: 2002-10 Impact factor: 6.318
Authors: John D Christensen; Andreea O Lungu; Elaine Cochran; Michael T Collins; Rachel I Gafni; James C Reynolds; Kristina I Rother; Phillip Gorden; Rebecca J Brown Journal: J Clin Endocrinol Metab Date: 2014-07-29 Impact factor: 5.958
Authors: Baris Akinci; Angela Subauste; Nevin Ajluni; Nazanene H Esfandiari; Rasimcan Meral; Adam H Neidert; Akin Eraslan; Rita Hench; Diana Rus; Barbara McKenna; Hero K Hussain; Thomas L Chenevert; Marwan K Tayeh; Amit R Rupani; Jeffrey W Innis; Christos S Mantzoros; Hari S Conjeevaram; Charles L Burant; Elif A Oral Journal: Med (N Y) Date: 2021-05-12
Authors: Thiago Bruder-Nascimento; Jessica L Faulkner; Stephen Haigh; Simone Kennard; Galina Antonova; Vijay S Patel; David J R Fulton; Weiqin Chen; Eric J Belin de Chantemèle Journal: Hypertension Date: 2019-10-28 Impact factor: 10.190
Authors: Marianna Beghini; Stephanie Brandt; Ingrid Körber; Katja Kohlsdorf; Heike Vollbach; Belinda Lennerz; Christian Denzer; Shlomit Shalitin; Ferruccio Santini; Werner F Blum; Julia von Schnurbein; Martin Wabitsch Journal: Int J Obes (Lond) Date: 2021-05-17 Impact factor: 5.095